QIAGEN has launched QIAsymphony Connect, an IVD-compliant platform for automated nucleic acid extraction, supporting up to 96 samples per run and compatible with existing QIAsymphony reagents and consumables.
Concert has issued a coverage policy deeming the EsoGuard Esophageal DNA Test medically necessary for eligible patients, with multiple client health plans now adopting the policy.
10x Genomics and Lausanne University Hospital have begun a multi-year study using single cell and spatial technologies to identify biomarkers predicting treatment response in patients with advanced solid tumors.
The company is showcasing newly cleared tests and platforms for multiple myeloma, lung cancer, connective tissue disease, and other laboratory applications.
Read More
The funding will support regulatory certification and the commercial launch of rapid tests for Lyme disease and sexually transmitted infections.
Read More
As Cyclospora infections surge in the US, laboratories face increased pressure to quickly differentiate cases, with the CDC reporting 1,947 confirmed infections and 98 hospitalizations across nine states as of July 24.
Read More
The program connects researchers with certified laboratories offering single-molecule PCR testing, technical support, and bioinformatics expertise.
Read More
The test uses intact circulating tumor cells instead of cell-free DNA fragments to analyze more than 500 genes and identify tumor markers.
Read More
Cepheid will debut its third-generation GeneXpert molecular testing system at ADLM 2024, featuring a touchscreen interface, updated software, and continued support for FDA-cleared tests and existing laboratory workflows.
Read More
Myriad Genetics has launched the FirstGene Multiple Prenatal Screen, a test that combines four prenatal genetic screens from a single blood draw as early as eight weeks gestation, according to the company.
Read More
Seegene has launched the Global Million Clinical Study to collect real-world data on the clinical utility of syndromic PCR testing for infectious diseases, aiming to inform future global diagnostic standards.
Read More
The deal adds a blood-based test for viral-mediated cancers to the company’s portfolio of transplant and cell therapy services.
Read More
Behavioral Diagnostics and Versiti Clinical Trial Solutions have partnered to provide epigenetic assays for objective smoking and alcohol exposure screening in clinical trials, aiming to improve participant risk assessment and data reliability.
Read More
QIAGEN’s FDA-cleared QIAstat-Dx panel detects Cyclospora cayetanensis, addressing a surge of over 1,600 confirmed US cases since May 2026.
Read More
Nabsys and Leiden University Medical Center are collaborating to evaluate an electronic genome mapping assay for improved detection of FSHD-associated repeat contractions, aiming to address current diagnostic limitations.
Read More
The fully automated, high-throughput assay for Hepatitis D virus RNA is available on cobas 5800/6800/8800 systems in CE mark-accepting countries.
Read More
Bio-Rad has launched Vericheck ddPCR kits for quality control in cell and gene therapy manufacturing, offering validated workflows for mycoplasma detection, capsid analysis, and residual DNA quantification.
Read More
The test utilizes genomic sequencing and AI to identify biological signals associated with early-stage disease.
Read More